BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

Core Insights - BioLineRx Ltd. has received a Notice of Allowance from the U.S. Patent and Trademark Office for a key patent covering the use of GLIX1 in treating cancers where cytidine deaminase (CDA) is not over-expressed, which accounts for over 90% of all cancers [1][2][3] - The patent extends GLIX1's protection until at least 2040, with a potential five-year extension, allowing the company to explore its application in various cancer types beyond glioblastoma [1][4] Company Overview - BioLineRx is a clinical development stage biopharmaceutical company focused on therapies in oncology and rare diseases, with its first approved product being APHEXDA® for stem cell mobilization in multiple myeloma [4][9] - The company is preparing to initiate a first-in-human study of GLIX1 in glioblastoma patients in Q1 2026 while advancing pre-clinical studies in other cancer models [3][5] Intellectual Property - The newly allowed patent is a significant addition to GLIX1's intellectual property portfolio, which includes both issued and pending patents that cover its use as a monotherapy and in combination with established anti-cancer agents [3][5] - GLIX1 is also covered by pending international patent applications for its use in treating homologous recombination proficient cancers, potentially extending patent protection until at least 2044 [5]